FOXO4-DRI Evidence Guide
Evidence for FOXO4-DRI is too preliminary to support a research protocol with confidence. All published data is from a single mouse model study, with no human pharmacokinetics, no safety data, and no independent replication. The senolytic concept is scientifically compelling, but this specific compound has not progressed to human investigation. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors have substantially more human evidence.
Our Take
Evidence for FOXO4-DRI is too preliminary to support a research protocol with confidence. All published data is from a single mouse model study, with no human pharmacokinetics, no safety data, and no independent replication. The senolytic concept is scientifically compelling, but this specific compound has not progressed to human investigation. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors have substantially more human evidence.
- Evidence context
- Senolytic mechanistic research, p21-mediated senescence models (mouse only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol
Benefits and Evidence
- Senescent Cell Clearance: Level D, mostly non-human evidence - In naturally aged and fast-aging mice, FOXO4-DRI selectively induced apoptosis in senescent cells, reducing senescence markers (p16, p21, SA-beta-gal) in multiple tissues.
- Organ Function Restoration: Level D, mostly non-human evidence - Aged mice treated with FOXO4-DRI showed improved renal function (reduced plasma creatinine and urea), restored fur density, and increased voluntary running activity.
- Physical Performance: Level D, mostly non-human evidence - Treated aged mice demonstrated increased exploratory behavior and willingness to run, suggesting improved physical fitness and reduced frailty.
Side Effects and Warnings
- Transient mild diarrhea (observed in mice)
- Potential off-target apoptosis at very high doses
- Unknown long-term effects
- No human trials have been conducted
- Self-administration is strongly discouraged due to lack of safety data
- Potential risk of excessive cell death if dosing is not carefully controlled
- May interfere with wound healing by eliminating beneficial senescent cells involved in tissue repair
Research Dosage References
- <strong>Intraperitoneal (animal studies)</strong> - 5 mg/kg - Three times per week for several weeks - Dosing is based on mouse studies only. No human dosing has been established.
Mechanism of Action
FOXO4-DRI is a protease-resistant D-amino acid retro-inverso peptide that penetrates cells and disrupts the FOXO4-p53 protein-protein interaction within PML nuclear bodies. By competitively binding p53, it releases p53 from FOXO4 sequestration, enabling p53 to translocate to mitochondria and activate the intrinsic apoptotic cascade (cytochrome c release, caspase activation) specifically in senescent cells that depend on this survival mechanism.
Legal Status
Research chemical; not approved for human use in any jurisdiction.
Primary Sources
- Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 2017.
- Senescence and the SASP: many therapeutic avenues. Genes & Development, 2010.
Quick Answers
Where is the strongest evidence for FOXO4-DRI?
Evidence for FOXO4-DRI is too preliminary to support a research protocol with confidence. All published data is from a single mouse model study, with no human pharmacokinetics, no safety data, and no independent replication. The senolytic concept is scientifically compelling, but this specific compound has not progressed to human investigation. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors have substantially more human evidence. Evidence context: Senolytic mechanistic research, p21-mediated senescence models (mouse only).
What are the main side effects of FOXO4-DRI?
FOXO4-DRI side effects and warning signals include Transient mild diarrhea (observed in mice), Potential off-target apoptosis at very high doses, Unknown long-term effects, No human trials have been conducted, and Self-administration is strongly discouraged due to lack of safety data.
What evidence level is FOXO4-DRI?
FOXO4-DRI is rated Level D; the listed research status is Preclinical.